1.
Clin Infect Dis
; 75(7): 1232-1234, 2022 Sep 30.
Article
in English
| MEDLINE | ID: covidwho-1806304
ABSTRACT
In an exploratory trial treating "long COVID" with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants. These findings suggest an unexpected mechanism of abnormal immune downmodulation in some persons that is normalized by leronlimab. Clinical Trials Registration. NCT04678830.